Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?

Company Overview - Amicus Therapeutics (FOLD) shares increased by 6.4% to close at $8.48, with trading volume significantly higher than usual, reflecting strong investor interest [1] - The stock has gained 7.7% over the past four weeks, indicating a positive trend [1] Product Performance - The rise in stock price is linked to strong sales of the company's lead product, Galafold, and the combination drug, Pombiliti + Opfolda [2] - Galafold generated sales of $233.1 million in the first half of 2025, marking an 11% year-over-year increase [2] - Pombiliti + Opfolda achieved sales of $46.8 million in the same period, representing a substantial 74% year-over-year growth [2] Earnings Expectations - Amicus Therapeutics is projected to report quarterly earnings of $0.12 per share, reflecting a 20% increase year-over-year [3] - Expected revenues for the upcoming quarter are $165 million, which is a 16.6% increase compared to the same quarter last year [3] - The consensus EPS estimate has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] Industry Context - Amicus Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Techne (TECH) [5] - Techne's stock closed 2.9% higher at $52.99, but has seen a negative return of 5.2% over the past month [5] - Techne's EPS estimate has remained unchanged at $0.42, indicating no growth compared to the previous year [6]